BNET Industries
OSI Pharmaceuticals Inc. (OSIP) is in the Pharma Industry
- Revenue
- Dec 31 2007
- $341.0M
- Profit
- Dec 31 2007
- $66.3M
- Market Cap
- Oct 09 2008
- $2.2B
Latest News and Analysis
OSI Pharmaceuticals Inc. Q2 2008 Earnings Call Transcript
Question-and-Answer SessionOperator Operator Instructions We'll go first to Joel Sendek with Lazard Capital Markets. Joel Sendek - Lazard Capital Markets Hi, thanks. My question has to do with the guidance on Tarceva. And I'm wondering what your assumptions are with regard to the split between Ex-US and US for...
OSI Pharmaceuticals Inc. Q1 2008 Earnings Call Transcript
Earnings Call ExcerptOSI Pharmaceuticals Inc. OSIP Q1 2008 Earnings Call May 06, 2008 5:00 pm ET Executives Kathy Galante - Head of IR and PR Colin Goddard - CEO Mike Atieh - CFO Gabe Leung - EVP and President of Oncology Analysts Terry Coyne - J.P. Morgan Maged Shenouda...
OSI Pharmaceuticals Inc. Q4 2007 Earnings Call Transcript
Earnings Call ExcerptOSI Pharmaceuticals Inc. OSI Q4 2007 Earnings Call February 21, 2008 5:00 pm ET Executives Kathy Galante - Head of IR and PR Colin Goddard - CEO Michael Atieh - CFO Gabe Leung - President of Oncology Analysts Geoff Meacham - JPMorgan Katherine Kim - Banc of...
Additional Resources
Viropharma, Lev Pharmaceuticals: An Attractive Biotech Pair
Dan Weiss submits: Lev Pharmaceuticals (LEVP.OB) is a biotechnology company, which has focused on developing a treatment for the serious, and potentially life-threatening disorder known as hereditary angioedema, which has no FDA approved treatments in the United States. Lev's treatment is known as Cinryze and the company is...
China Biologic to Buy Majority Interest in Plasma Competitor
ChinaBio Today submits: China Biologic Products (CBPO.OB) will pay $28.5 million to gain control of one of its competitors in the business of plasma-based pharmaceuticals. China Biologic will buy a 90% stake in Chongqing Dalin Biologic Technologies Co., Ltd. Dalin, in turn, owns a 54% equity interest in Qianfeng...
Genesis Pharma Books 31% Higher Revenues in 2008
ChinaBio Today submits: Genesis Pharmaceuticals Enterprises (GNPH.OB) released its 2008 full-year (ended June 30) financial report, showing that the company continues to do well. In 2008, revenues for the company climbed 31% to $99.5 million, though net income was up a minuscule 2% at $22.5 million. The net income...
Eli Lilly in Talks to Buy ImClone: Sources
By Jessica HallPHILADELPHIA (Reuters) - ImClone Systems Inc IMCL is in talks to be acquired by Eli Lilly and Co LLY, sources familiar with the situation said on Wednesday, after ImClone had rebuffed a sweetened takeover offer from Bristol-Myers Squibb Co BMY.Eli Lilly has offered to buy ImClone, which makes...
Johnson & Johnson: A Defensive, Less Volatile Investment Option
J Clinton Hill submits: Investors looking for a defensive play should consider Johnson & Johnson JNJ, the global health care leader with exposure to growing baby boomer demographics and reliable customers like medicare and medical. The company is a floating battleship in this unstable market environment. With a market cap...
Merck KGaA Open to Taking Part in ImClone Bid
FRANKFURT (Reuters) - Merck KGaA MRCD would not bid for ImClone Systems Inc IMCL on its own, but may consider taking part in a potential approach for the U.S. drugmaker, Merck's Chief Executive Karl-Ludwig Kley said."We are not the white knight ... but if anyone contacts us to ask whether...
Alpharma Rejects King Pharma's Offer; What Now?
The M & A Researcher submits: Alpharma ALO has announced the rejection of King Pharmaceuticals' KG unsolicited $37 per share offer as "financially inadequate." ALO has also disclosed the following with respect to third-party interest: by The M & A Researcher
Indevus: Making Big Gains with Approval for Its New Drug
Andrew Snyder submits: Indevus Pharmaceuticals IDEV was up by over 100% Friday. The big gains come thanks to positive news from the FDA and company executives signing a great business deal with Teva Pharmaceutical TEVA. As the Wall Street mess is cleaned up, we will be seeing more...
Court Ruling Raises Concerns About Ariad's Conduct and Patents
Derek Lowe submits: Over the years on this blog, I’ve written quite a few times about Ariad Pharmaceuticals ARIA and their quest to assert some rather sweeping patent rights. For background, see here and search for "Ariad" - there's a lot to read, if you're in the mood. The...
Eli Lilly's Lechleiter Does Shameless U-turn on Payments to Doctors
Eli Lilly CEO John Lechleiter has done a spectacular about-face on the issue of disclosing the drug company's payments to doctors. Last week he was against it. Today he's suddenly in favor of it. Let's be clear, Lechleiter is doing the right thing by creating "an online...
EPIX Pharmaceuticals Inc. Q2 2008 Earnings Call Transcript
Earnings Call ExcerptEPIX Pharmaceuticals Inc. EPIX Q2 2008 Earnings Call August 7, 2008 10:00 am ET Executives Elkan Gamzu - Interim Chief Executive Officer Kimberlee Cobleigh Drapkin - Chief Financial Officer Analysts Mike Yee - RBC Capital Markets Alan Carr - Needham & Co Jon Lecroy -...
Titan Pharmaceuticals, Inc. Q2 2008 Earnings Call Transcript
Question-and-Answer Session Operator Operator instructions Our first question comes from the line of Ram Selvaraju from Rodman & Renshaw. Please proceed. Ram Selvaraju – Rodman & Renshaw Hi, thanks very much for taking my question. First of all, Marc, if you could just reiterate the P-values...
Tate & Lyle Shares Sour on Sweetener Patent Defeat
By Mark PotterLONDON (Reuters UK) - Tate & Lyle TATE has lost a U.S. patent case against manufacturers and importers of Chinese sucralose, its super sweetener sold under the name Splenda, sending its shares plunging 17 percent to a 4-year low.The sugar, sweetener and industrial starches group said on Tuesday...
Lilly and GSK Emit Smoke, But No Fire, In Massachusetts Legal Flap
Eli Lilly CEO John Lechleiter pictured has joined the bizarre political pantomime surrounding the new Massachusetts law requiring drug companies to detail the payments they make to doctors. He told the Boston Business Journal: Life sciences investment will be scared away ... [the law has the potential to] subject...
Sunesis: Publish or Perish?
Derek Lowe submits: A colleague mentioned to me the other day that Sunesis Pharmaceuticals SNSS had let many of its remaining research staff go back during the summer – they’re battening down to try to get their main clinical candidate through for leukemia and ovarian cancer. That’s a common...
Analysts Express Confidence in Biovail's New Strategy
FP Trading Desk submits: Biovail Corp.'s BVF acquisition of Prestwick Pharmaceuticals on Wednesday may not have been well received by investors, but according to RBC Capital analyst Douglas Miehm, it is a move in the right direction for the pharmaceutical company in transition. On Wednesday, Biovail said it bought...
EU Court Gives Mixed Verdict in Glaxo Case
By Huw Jones BRUSSELS (Reuters UK) - A drug company can curb trading in its own products only if faced with larger-than-normal orders, the European Union's top court said on Tuesday in a case involving UK drug giant GlaxoSmithKline GSK. Glaxo had tried to crack down...
- Next »
- page 1 of 1
- « Previous
Sort byClose
View Related Content by Tag Close
- Incorporated: 1983
- CEO: Dr. Colin Goddard
- Employees: 488
OSI Pharmaceuticals is a biotechnology company that discovers, develops and commercializes molecular targeted therapies, addressing unmet medical needs in oncology, diabetes and obesity. Co.'s flagship product, Tarceva?, is an oral, once-a-day, small molecule inhibitor of the epidermal growth factor receptor (HER1/EGFR), the treatment of advanced non-small cell lung cancer patients who have failed at least one prior chemotherapy regimen, and for the treatment of patients with locally advanced and metastatic pancreatic cancer in combination with the gemcitabine. Co. co-promotes Tarceva in the U.S. with Genentech, Inc. and receives royalties on sales from its international partner, Roche.
Key Competitors
OSI Pharmaceuticals Inc. Company Info
Board of Directors
Mr. Robert A. Ingram
Chairman
Ms. Katharine B. Stevenson
Mr. John P. White
Dr. Colin Goddard
Mr. Santo J. Costa
Dr. Daryl K. Granner
Mr. Joseph Klein III
Mr. Kenneth B. Lee Jr.
Dr. Viren Mehta
Mr. David W. Niemiec
Dr. Herbert Pinedo Ph.D.
Contact Information
41 Pinelawn Road
Melville, NY
631 962-2000
NAICS Code
In-Vitro Diagnostic Substance Manufacturing: 325413
